Repository of the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association

https://edoc.mdc-berlin.de/20244

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.

Bohl S.R., Schmalbrock L.K., Bauhuf I., Meyer T., Dolnik A., Szyska M., Blätte T.J., Knödler S., Röhner L., Miller D., Kull M., Langer C., Döhner H., Letai A., Damm F., Heckl D., Bullinger L., Krönke J.

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma

Stephan R. Bohl,[1,2,*] Laura K. Schmalbrock,[1,3,4,*] Imke Bauhuf,[1,*] Tatjana Meyer,[1] Anna Dolnik,[3] Martin Szyska,[3] Tamara J. Blätte,[3] Sarah Knödler,[1] Linda Röhner,[1] Denise Miller,[1] Miriam Kull,[1] Christian Langer,[5] Hartmut Döhner,[1] Anthony Letai,[2] Frederik Damm,[3] Dirk Heckl,[6] Lars Bullinger,[3,4] and Jan Krönke[1,3]

[1]Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany; [2]Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; [3]Department of Hematology, Oncology and Tumor Immunology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; [4]Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany; [5]Department of Hematology, Internal Oncology and Palliative Care, Kempten Hospital, Kempten, Germany; and [6]Department of Hematology and Oncology Children's Hospital, Halle University Hospital, Halle, Germany

Key Points

- Relapse-associated genetic alterations are functionally linked to drug-specific resistance.

- Genetic inactivation of DNA damage repair pathway regulators enhances sensitivity to cytotoxic chemotherapy.

The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma (MM). However, the majority of patients eventually relapse and become resistant to one or multiple drugs. While the genetic landscape of relapsed/ resistant multiple myeloma has been elucidated, the causal relationship between relapse-specific gene mutations and the sensitivity to a given drug in MM has not systematically been evaluated. To determine the functional impact of gene mutations, we performed combined whole-exome sequencing (WES) of longitudinal patient samples with CRISPR-Cas9 drug resistance screens for lenalidomide, bortezomib, dexamethasone, and melphalan. WES of longitudinal samples from 16 MM patients identified a large number of mutations in each patient that were newly acquired or evolved from a small subclone (median 9, range 1-55), including recurrent mutations in *TP53*, *DNAH5*, and *WSCD2*. Focused CRISPR-Cas9 resistance screens against 170 relapse-specific mutations functionally linked 15 of them to drug resistance. These included cereblon E3 ligase complex members for lenalidomide, structural genes *PCDHA5* and *ANKMY2* for dexamethasone, *RB1* and *CDK2NC* for bortezomib, and *TP53* for melphalan. In contrast, inactivation of genes involved in the DNA damage repair pathway, including *ATM*, *FANCA*, *RAD54B*, and *BRCC3*, enhanced susceptibility to cytotoxic chemotherapy. Resistance patterns were highly drug specific with low overlap and highly correlated with the treatment-dependent clonal evolution in patients. The functional association of specific genetic alterations with drug sensitivity will help to personalize treatment of MM in the future.

Introduction

Multiple myeloma (MM) is a genetically heterogeneous malignant plasma cell disease characterized by a high number of somatic chromosomal alterations and gene mutations.[1-4] Furthermore, MM displays a high degree of intraclonal genetic heterogeneity that evolves under therapeutic pressure with selection of therapy resistant subclones.[5-8]

Current treatment regimens for newly diagnosed MM consist of a combination of an immunomodulatory drug (IMiD) like lenalidomide, proteasome inhibitors like bortezomib and carfilzomib, glucocorticoids

such as dexamethasone, and chemotherapy.[9] These combinations result in high response rates and remission for several years in most patients. However, even with intensive therapy regimens that comprise high-dose melphalan/autologous stem cell transplantation (auto-PBSCT) and lenalidomide maintenance, long-term remissions or cures are rare, and most patients relapse within several years due to acquired drug resistance of MM cells.[10] Several studies have found gene mutations and chromosomal aberrations that are enriched in resistant/relapsed MM.[3,8,11-15] Chromosomal aberrations like deletion 17p (del17p) comprising *TP53* and amplification of 1q21 are consistently associated with a poor outcome and are enriched at relapse,[14,15] implying that these aberrations impair drug sensitivity. Likewise, homozygous loss of tumor suppressor genes due to chromosomal deletions and/or mutations, including *CDKN2C*, *RB1*, *TRAF3*, *BIRC3*, and *TP53*, are more frequently observed in relapsed/refractory disease and are predictors of a poor prognosis.[14] Inactivation of *TP53* reduces activity of cytotoxic chemotherapy in MM and other types of cancer, providing a functional link between a genetic alteration and response to a drug.[16-18] The cereblon (CRBN)-CRL4 E3 ligase, the target of all IMiDs, that also comprises *DDB1* and *CUL4* is genetically or transcriptionally impaired in 10% to 20% of MM patients refractory to lenalidomide or pomalidomide.[11,19] Consistently, genome-wide CRISPR-Cas9–based resistance screens found inactivation of *CRBN* and other members of the CRBN-CRL4 E3 ubiquitin ligase complex to cause resistance to IMiDs in the MM1S MM cell line.[20,21] A genome-wide screen identified inactivation of proteasome subunit proteasome 26S subunit, *PSMC6* to cause bortezomib resistance.[22] However, besides *CRBN*, genes that were found to be functionally associated with lenalidomide and bortezomib drug resistance in these screens are rarely mutated in MM patients.[8,11] Vice versa, for most genetic alterations found in MM, the functional impact on drug sensitivity is not clear. Multidrug combinations used in MM treatment make it challenging to infer the impact of a distinct gene mutation on activity to a specific drug. In this study, we performed pairwise comparison of whole-exome sequencing (WES) from pretreatment and relapsed MM samples followed by functional CRISPR-Cas9 resistance screens in order to systematically determine the impact of inactivation of individual genes on the activity of the 4 most frequently used drugs in the treatment of MM: bortezomib, lenalidomide, dexamethasone, and melphalan.

Materials and methods

Study cohort

We included 16 patients with newly diagnosed MM (n = 15) and plasma cell leukemia (n = 1) in our study (Table 1). All patients provided informed consent to molecular studies according to the Declaration of Helsinki, and the study was approved by the local ethics committee of the University of Ulm, Germany.

Exome sequencing

Exome sequencing was performed in a total of 38 samples obtained at diagnosis and ≥1 time point during disease progression in all patients (n = 16). For 4 patients, 2 serial samples and in 1 patient, 3 serial samples were available at disease progression. Pretreatment/ progress samples were derived from bone marrow (BM; n = 37) or peripheral blood (n = 1). Genomic DNA (gDNA) was extracted using the AllPrep DNA/RNA kit (Qiagen). Blood without evidence of

Table 1. Clinical characteristics of the study cohort

Variable at diagnosis	Value
Age, y	
Median (range)	64 (45-79)
Sex, n (%)	
Male	14 (88)
Female	2 (12)
Type of MM, n (%)	
IgA	8 (50)
IgG	8 (50)
κ	8 (50)
Λ	8 (50)
Cytogenetics at diagnosis, n (%)	
t(4;14)	5 (31)
t(11;14)	4 (25)
t(14;16)	2 (13)
del13q14	6 (38)
del17p	1 (6)
+9q34	6 (38)
+1q21	11 (69)
Treatment, n (%)	
Low-dose melphalan	4 (25)
High-dose melphalan/autologous SCT	10 (63)
Lenalidomide	16 (100)
Bortezomib	9 (56)
Dexamethasone/prednisolone	16 (100)

Ig, immunoglobulin; SCT, stem cell transplantation.

circulating plasma cells was used as nontumor control. Library preparation for WES was performed with the Nextera Rapid Capture Exome kit (Illumina) with 50 ng gDNA input followed by sequencing on an Illumina HiSeq 2000 platform using the 200-cycle TruSeq SBS v3 kit (Illumina) according to the manufacturer's instructions. The median coverage of all sequenced samples was 130× (supplemental Table 1). The read counts were adjusted for plasma cell content. One follow-up sample (#3, second relapse) was excluded for analysis of number and stability of mutations due to low sequencing quality at various positions but could be analyzed for the presence of recurrent gene mutations and clonal evolution of these mutations. WES data analysis and visualization of the clonal evolution with fishplots were performed using an in-house analysis pipeline.[23] A variant allele frequency (VAF) >5% was defined for variant calling. The presence of subclonal variants at the time of diagnosis was determined for selected genes using an ultra-deep sequencing approach as described previously[24] and detailed in supplemental Methods.

CRISPR-Cas9 screens

Cas9-expressing MM1S, KMS-27, NCI-H929, OPM2, and RPMI8226 cells were infected with the custom-made lentiviral single guide RNA (sgRNA) library (supplemental Table 2). To maintain an sgRNA coverage of 1000×, 10 million cells were infected at ∼0.3 multiplicity of infection (transduction rate 30%) to

limit the number of sgRNAs per cell to 1. Cells were split at day 4 and distributed to treatment with lenalidomide, bortezomib, dexamethasone, melphalan, or dimethyl sulfoxide (DMSO) (all compounds from Selleck Chemicals, Houston, TX) as control (supplemental Table 3). Every 3 days, the media was replaced with fresh media containing the drug or DMSO. At the end of the screen (28-35 days depending on cell doubling time), or if cell viability was <10%, cells were harvested and gDNA was isolated using the Qiagen DNA isolation kit. PCR amplification of the sgRNA sequences (supplemental Table 2) was performed using barcoded primers (supplemental Table 4). Next-generation sequencing of the amplicons was performed on an Illumina MiSeq.[25] The abundance of each sgRNA in a sample was assessed by an in-house python script. The MaGeCK software algorithm[26] was used to calculate the P value and false discovery rate (FDR) values for each gene and sgRNA. The calculated z-score for each gene is based on the median sgRNA log2 fold change per gene.

Results

Clonal evolution in relapsed MM

Sixteen patients with MM with available pretreatment and ≥1 progression sample were included in the study. The median age of the patients was 64 years (range 45-79 years). Treatment comprised melphalan in 14 patients (88%), lenalidomide in 16 patients (100%), bortezomib in 9 patients (56%), and dexamethasone in 16 patients (100%) (Table 1). The median time between pretreatment and progression samples was 26 months (range 2-86 months) (supplemental Table 5).

Fluorescence in situ hybridization analyses revealed the presence of a chromosomal translocation in 11 patients (69%; 31% t(4;14), 33% t(11;14), and 13% t(14;16)) that persisted in all cases analyzed. Copy-number alterations at diagnosis were gain at 9q indicating a hyperdiploid karyotype in 6 patients (38%), gain at 1q21 in 11 patients (69%), del13q14 in 6 patients (38%), and del17p13 in 1 patient (6%). At relapse, 3 out of 14 patients (21%) acquired del13q14, 2 out of 14 patients (14%) acquired a new +1q21, 1 patient displayed a del13q14, and 1 patient lost a +9q34 (supplemental Figure 1).

The median number of mutations detected by WES was similar at diagnosis (median 30, range 10-207) and relapse (median 40, range 9-227, P = .33). The majority of mutations was stable between diagnosis and relapse indicated by the number of mutations shared in both samples (730/1162; 63%). Eighty-one (7%) mutations were found only at diagnosis and 351 (30%) only at relapse (Figure 1A). Between individual patients, the percentage of stable mutations between diagnosis and the first progression sample varied (Figure 1A-B; supplemental Figure 2). In all patients ≥1 new mutation was gained at relapse (median 9, range 1-55), and in addition, a median of 2 (range 0-20) gene mutations showed an increase of the VAF >10% between diagnosis and relapse samples for a total number of acquired/increased mutations of 10 (range 1-56) per patient. In contrast, a median of 4 (range 0-8) mutations detected at diagnosis were not present at disease progression, and the VAF decreased >10% in a median of 11 (range 0-141) mutations for a total median number of lost/decreased mutations of 13 (range 1-141). In 4 patients (patients 6-8 and 11) with serial progression samples, a median of 3 (range 0-15) mutations were newly acquired or increased with a VAF

>10% and only few mutations were lost or decreased in the second relapse sample (median 3, range 0-11).

In general, we observed a high degree of interindividual genetic heterogeneity with only few recurrently mutated genes in pretreatment and progression samples. At diagnosis, we found recurrent mutations in ≥2 patients in 17 genes including KRAS (n = 4), NRAS (n = 3), BRAF (n = 2), DIS3 (n = 3) and IGLL5 (n = 3) (Figure 1C). At the time of progression most of these mutations were stable with one patient acquiring a KRAS mutation. In contrast, 4 patients acquired mutations in DNAH5 and 3 in WSCD2. TP53 mutations were detected by WES in 4 patients at relapse and persisted in subsequent follow-up samples (Figure 1C, supplemental Table 6A). In order to determine whether relapse-specific mutations were newly acquired or present at diagnosis, we performed ultra-deep targeted resequencing for selected relapse-specific genes in diagnostic specimen. For 3 of 4 cases with TP53 mutation identified by WES at relapse, we found the exact same mutation in a small subclone (VAF 0.1%-6.7%) in the pretreatment sample, implying that they expanded under therapy. (supplemental Table 6B).

Although all patients received lenalidomide, only 1 clonal outgrowth of a DDB1-mutation–harboring clone was detected, and 1 newly acquired subclonal IKZF3 mutation was found at relapse. No mutations in other genes involved in IMiD activity, including CRBN, CUL4B, IKZF1, CSNK1A1, MCT1, or CD147, were found.[27-31]

CRISPR-Cas9 knockout screens in MM reveal drug-specific resistance and sensitivity

In order to investigate the functional impact of the identified relapse-specific gene mutations on sensitivity to 4 commonly used drugs in MM, we performed pooled CRISPR-Cas9–based knockout resistance screens for melphalan, dexamethasone, bortezomib, and lenalidomide. To exclude cell-line–specific effects, the screens were performed in 5 MM cell lines of different genetic background (supplemental Table 7): MM1S, OPM2, NCI-H929, RPMI, and KMS-27. The screening included 156 genes that were found mutated at progression and fulfilled following criteria: (1) VAF of >20% at the time of progression, (2) found exclusively in progression samples with a >10% VAF or more than twofold increase of VAF at progression, (3) CRBN binders, and (4) predicted to be loss of function (supplemental Tables 8 and 9). In addition, we included genes that were found to be recurrently mutated and enriched in relapsed/refractory MM in previously published studies (supplemental Table 10).[3,7,11,21,32] Each gene was targeted by 4 different sgRNAs. In addition, 30 control nontargeting sgRNAs and 30 sgRNAs against pan-essential genes were included as positive controls for a total of 745 sgRNAs. Two independent screens performed in MM1S cells demonstrated a high reliability (Pearson correlation r = 0.60, P < .0001) (supplemental Figure 3). The nontargeting control sgRNAs displayed a stable read count, while sgRNAs targeting essential genes were depleted at the end of the screen in the DMSO control in all 5 cell lines (supplemental Figure 3 and supplemental Table 11). sgRNAs targeting 2 frequently mutated genes in MM, TRAF3 and FAM46c, were enriched in the absence of a drug in the respective wild-type cell lines, but not in those that carry inactivating mutations (supplemental Figure 4). Each drug in our CRISPR screen revealed genes whose inactivation

Figure 1. Gene mutations in pretreatment and relapse MM samples detected by WES. (A) Number of mutations at diagnosis (gray) and acquired mutations in serial relapse time points (red, relapse 1; yellow, relapse 2; green, relapse 3). Each bar shows the total number of mutations at the respective time point (D, diagnosis; R, relapse) in individual patients. Treatments with dexamethasone, immunomodulatory drugs (IMiD), bortezomib and melphalan before the acquisition of the sample are indicated below. (B) Distribution of mutations (number (%)) detected at diagnosis and in relapse samples. Mutations present only at diagnosis are color-coded in blue, mutations present at both time points in gray, and mutations present only at relapse in red. Dashed lines indicate the proportion of mutations with a VAF increase >10% at relapse. (C) Recurrent gene mutations at diagnosis and relapse. Each column represents 1 patient. For each gene, the presence of a mutation (color-coded in red; dark gray indicates no mutations was detected) at different time points is indicated in subsequent rows. On the right-hand side, the frequency of mutated patients at diagnosis and at relapse is given. UPN, unique patient number.

caused resistance. These genes were highly drug-specific, with little overlap between the tested drugs (Figure 2).[33]

Alterations in DNA damage repair genes affect sensitivity to melphalan

Melphalan is an alkylating cytotoxic agent that induces apoptosis in cells by induction of DNA damage. CRISPR-Cas9 screens in the presence of melphalan revealed sgRNAs targeting 4 of the 177 included genes (2%) to be significantly enriched indicating

resistance in ≥1 of the 5 cell lines (Figure 3). *TP53* was the only gene that scored in the 2 *TP53* wild-type cell line (MM1S and NCI-H929) screen (z-score 2.5, FDR < 0.1, *P* < .05), and experiments with individual sgRNAs validated these findings (Figure 3D). In contrast, in the 3 other cell lines carrying inactivating *TP53* mutations (KMS27, OPM2, and RPMI8226), all sgRNAs targeting *TP53* had no additional effect.[34-37] Further genes were only enriched in individual cell lines and included *VPS35* (z-score 3.2), *NDUFA10* (z-score 2.8), *SMARCD2* (z-score 3.7), and *CHD8* (z-score 3.1) (Figure 3A-B).

Figure 2. Heatmap of genes scoring significantly in CRISPR-Cas9 screens. SgRNAs targeting the listed genes conferred resistance (red) or sensitivity (blue) to ≥1 of the tested drugs (Bor, bortezomib; Dex, dexamethasone; Len, lenalidomide; Mel, melphalan) in ≥1 cell line. A cross indicates that the cell line carries a mutation in the respective gene (according to the Cancer Cell Line Encyclopedia database[33]).

In addition to sgRNAs causing resistance, we also found sgRNAs that were depleted in melphalan-treated cells, indicating that inactivation of the targeted genes increases sensitivity to melphalan (Figure 3C-D; supplemental Figure 6A,C). The top sensitizing hits were members of the DNA damage repair pathway: *FANCA* (5/5 cell lines, z-score −5.8), *RAD54B* (3/5 cell lines, z-score −5.5), *ATM* (3/5 cell lines, z-score −3.6), and *BRCC3* (2/5 cell lines, z-score −3.19). In independent experiments using single sgRNAs, inactivation of *FANCA* increased DNA damage and apoptosis and diminished cell viability after melphalan treatment (supplemental Figure 6B-C).

Other genes whose inactivation increased sensitivity in a single cell line were *SMARCD2* (z-score −3.2), *SETD2* (z-score −2.5), and *RIC1* (z-score −2.4).

The functional association of gene inactivation and drug sensitivity found in our screens highly correlated with the clinical course in patients; in 3 patients (patients 7, 8, and 14), a *TP53*-mutated clone strongly evolved under melphalan therapy (Figure 3E; supplemental Figure 7). In patient 13, we detected a new *VPS35* mutation after 2 courses of high-dose melphalan and tandem auto-PBSCT.

Inactivation of CRBN-CRL4 E3 ligase members confer resistance to lenalidomide

In the lenalidomide resistance screens, we found 3 genes whose inactivation by CRISPR-Cas9 conferred resistance in ≥1 cell line (Figure 2). The 4 most-enriched sgRNAs in all 5 cell lines targeted *CRBN* (z-score 9.2), the target of all IMiDs and substrate receptor of the CRL4 E3 ubiquitin ligase (Figure 4A-B; supplemental Figure 5A). sgRNAs targeting 2 other members of the E3 ligase,

CUL4B (z-score 3.3) and *DDB1* (z-score 3.7), were significantly enriched after lenalidomide treatment in 2 and 1 cell lines, respectively. In MM1S cells, *DDB1* was slightly above the FDR threshold of 0.1, with a *P* value < .05. None of the other genes were associated with reduced or increased lenalidomide sensitivity. Consistent with the essential role of the CRBN-CRL4 E3 ligase for IMiD activity, we observed expansion of a *DDB1*-mutated subclone in patient 3 during a lenalidomide-comprising second-line treatment (Figure 4C).

Loss of cell-cycle regulators impair bortezomib activity

The clinical activity of proteasome inhibitors in MM is reflected by a high sensitivity of MM cell lines in vitro. In CRISPR-Cas9 screens performed with continuous low-dose bortezomib (1-3 nM), we found significantly enriched or depleted sgRNAs in OPM2, but not in the other cell lines (Figure 2). sgRNAs targeting *VPS35* (z-score 3.1) and *ZNF236* (z-score 2.67), a zinc-finger protein of unknown function, caused resistance, while sgRNAs targeting *NFKB2* (z-score −2.6) and *RIC1* (z-score −2.9) enhanced sensitivity to bortezomib (Figure 5A-C).

Because of these low numbers of resistance genes identified in 5 cell lines for continuous exposure to bortezomib, we explored an alternative treatment approach. Bortezomib and other proteasome inhibitors in MM treatment are applied once or twice weekly resulting in a high peak plasma concentration of ~100 nM within 1 hour followed by a steep decline over 4 hours and a slower decline in the terminal phase.[37,38] We therefore performed a bortezomib CRISPR-Cas9 resistance screen in MM1S cells

Figure 3. CRISPR-Cas9 screens in melphalan-treated MM cell lines. (A) sgRNA library ranked by z-score for MM1S cells treated with 2 μM melphalan. (B) z-score for the 4 different sgRNAs for genes that were significantly enriched (red) or depleted (blue) in the CRISPR-Cas9 screen in ≥1 cell line. (C) MM1S-Cas9 cells lentivirally expressing sgRNAs against *luciferase* (Luc), *FANCA*-, or *TP53* were analyzed for knockout efficiency by western blot. Data are representative of 2 biological replicates. (D) MM1S-Cas9 cells were infected with Luc control- or *FANCA*-specific sgRNAs and treated with DMSO, melphalan, or lenalidomide for 7 days. Dose-response curves show viability normalized to DMSO treatment assessed by CellTiter-Glo. Error bars represent standard error of the mean for each drug concentration. (E) Treatment, paraprotein course (purple graph), and fishplots showing the clonal evolution from diagnosis to relapse in patient 8. Arrows indicate collection of BM samples (Thal, thalidomide).

mimicking these drug kinetics. The cells were exposed to high bortezomib concentrations (20 nM and 100 nM) for only 1 and 4 hours, and the treatment was repeated after 7 days. Here, sgRNAs targeting the cell-cycle regulators *RB1* (z-score 1.9) and *CDKN2C* (z-score 2.3), both found homozygously deleted in relapsed MM,[15] were enriched in all treatment conditions (Figures 5A-C and 2).

Dexamethasone efficacy is affected by mutations in structural genes and the NF-κB pathway

Dexamethasone is a glucocorticoid with high clinical activity in MM and other lymphoid malignancies. In the dexamethasone resistance CRISPR-Cas9 screens, we found a total of 6 genes whose sgRNAs were significantly enriched in ≥1 cell line (Figure 2). sgRNAs

targeting *ANKMY2*, a downstream activator of the sonic hedgehog signaling pathway,[39,40] were highly enriched in MM1S (z-score 2.28) and NCI-H929 cells (z-score 2.0). In MM1S cells, we found additional sgRNAs enriched targeting the cadherin superfamily gene members *PCDHA5* (z-score 4.68) and *PCDHGB4* (z-score 1.3) (Figure 6A-B). Individual evaluation of sgRNAs targeting *PCDHA5 and PCDHGB4* showed a reduction of dexamethasone sensitivity over a broad range of concentrations (Figure 6C). The protocadherin gene locus is located on chromosome 5 around 2 megabases upstream of the glucocorticoid receptor gene locus *NR3C1*, which prompted us to evaluate whether sgRNAs targeting *PCDHA5* and *PCDHGB4* cause dexamethasone resistance through downregulation of *NR3C1* by targeting regulatory regions or through introduction of large genetic deletions. We found that

Figure 4. CRISPR-Cas9 screens in lenalidomide-treated MM cell lines. (A) sgRNA waterfallplot of MM1S cells treated with 1μM lenalidomide. (B) Significant his per cell line ranked by sgRNA z-score. (C) Clinical course (treatment schedule and paraprotein) of patient 3 and clonal evolution of mutations during sequential treatments. Arrows indicate collection of BM biopsy (auto, autologous stem cell transplantation; Bort, bortezomib; Cy, cyclophosphamide).

NR3C1 protein levels remained unchanged after *PCDHA5* and *PCDHGB4* inactivation, implying a different mode of action for dexamethasone resistance (supplemental Figure 8). Consistent with the dexamethasone-specific resistance identified by CRISPR-Cas9 screens, we found a clone with an *ANKMY2* and *PCDHGB4* mutation in a relapse sample (patient 1) after 3 years of dexamethasone-comprising therapy (Figure 6D).

In dexamethasone-treated MM1S cells, we found additional sgRNAs enriched targeting the CRL4 E3 ligase member *CUL4B*

(z-score 0.8) and *BIRC3* (z-score 1.6). In NCI-H929 cells, sgRNAs targeting the NF-κB and interleukin-6 signaling protein *TRAF3*[40] (z-score 2.7) were enriched after dexamethasone treatment. Of note, MM1S cells carry a *TRAF3* mutation, and thus, sgRNAs targeting *TRAF3* likely had no additional effect.

Our CRISPR screens for dexamethasone also revealed genes whose inactivation was associated with increased sensitivity (Figure 2). In MM1S, the 2 top hits were *LEMD3* (z-score −3.8) and *SMARCD2* (z-score −4.4). We detected *LEMD3* and *SMARCD2* mutations

Figure 5. CRISPR-Cas9 screens in bortezomib-treated MM cell lines. (A) sgRNA waterfallplot for OPM2 cells treated continuously with 3 nM bortezomib. (B) sgRNA waterfallplot for MM1S cells treated continuously with 1 nM bortezomib or intermittent treatment with 100 nM for 4 hours. (C) Significant his per cell line ranked by sgRNA z-score

in 3 relapse samples of patient 7, who responded to a dexamethasone-containing treatment of >1 year. Knockout of the non-canonical poly(A) polymerase *FAM46c* (z-score −3.5) enhanced dexamethasone sensitivity in KMS27 cells (Figure 6B) but did not score in MM1S and NCI-H929, which already harbor a *FAM46c* missense mutation (supplemental Table 7).[41,42] Consistently, a *FAM46c*-mutated clone detected at diagnosis of patient 14 decreased under a dexamethasone-comprising treatment.

Discussion

This is the first study coupling comprehensive genetic profiling with functional genomics to systematically study the mutational dynamics in putative tumor suppressor genes and drug activity in MM. In our longitudinal study, WES of pretreatment and progression samples revealed a high number of gene mutations newly acquired in progression samples or expanding from a small subclone present at diagnosis, which is consistent with previous studies.[5,7,8] While many of recurrent MM mutations, like in *RAS* and *DIS3*, persisted during therapy, other mutations, like those in *DNAH5*, *WSCD2*, and *TP53*, were enriched in relapse samples. Our CRISPR resistance screens revealed that on average, 1 or 2 of the median 9 mutations acquired in an individual relapse sample could be functionally linked to drug sensitivity. Among the most recurrent mutations at relapse were those in *TP53*, which occurred predominantly after cytotoxic chemotherapy treatment. Targeted deep sequencing of the pretreatment samples revealed that in all patients analyzed a very small *TP53*-mutated subclone preexisted and expanded under therapy. Previous reports similarly found a higher incidence of inactivating *TP53* mutations and deletions in relapsed/ refractory disease[8,11,43]

and an association with adverse outcome in MM patients treated with chemotherapy.[15,17,43,44] Our functional genetic analyses revealed that these observations are explained by reduced melphalan sensitivity of *TP53*-mutated cells. *TP53* inactivation did not functionally affect sensitivity to dexamethasone, lenalidomide, or bortezomib. In accordance, in patients receiving bortezomib before and after chemotherapy, the chromosomal aberration del17p comprising *TP53* had no effect on outcome.[45,46]

On the contrary, we found that inactivation of genes involved in chromosome stability and DNA damage repair enhanced sensitivity to melphalan, even in cells with coexisting *TP53* mutations. For *FANCA*, we have shown that inactivation enhances DNA damage upon chemotherapy, which is in line with previous findings in MM[17,47] and other malignancies.[48-50] In relapsed MM, mutations in the DNA damage repair pathway are found in up to 20% of patients (supplemental Table 10).[8,11] Our findings imply that these patients might benefit from cytotoxic therapy and possibly other therapies targeting the DNA repair mechanism, like PARP or ATR inhibition.[51,52] This is especially important given that chemotherapy-based regimens are nowadays less frequently applied in relapsed MM in favor of chemotherapy-free regimens with new drugs like antibodies, next-generation IMiDs, and proteasome inhibitors.

In our CRISPR-Cas9 screens, inactivation of *CRBN* or other CRL4 E3 ligase complex members (*DDB1* and *CUL4B*) caused resistance to lenalidomide, consistent with previous studies.[11,20,21] The discrepancy of the essential functional role of the CRBN-CRL4 ligase and the low frequency of mutations in these genes is currently not explained. Remarkably, we could not link any other gene inactivation, including high-risk deletions/mutations in *TP53*,

Figure 6. CRISPR-Cas9 screen in dexamethasone-treated myeloma cell lines. (A) sgRNA waterfallplot of MM1S cells treated with 60 nM dexamethasone. (B) Significant hits from CRISPR-Cas9 screens for all cell lines. (C) Cell viability of KMS27- and MM1S-Cas9 cells expressing gene targeting (*PCDHGB4*, *PCDHA5*, and *FAM46c*) or control sgRNAs after treatment with DMSO or dexamethasone for 4 days. (D) Paraprotein course and clonal evolution of patient 1 (Pred, prednisolone; Pom, pomalidomide).

BIRC3, or *RB1*,[15,32] to lenalidomide sensitivity, suggesting that other, not genetically defined resistance mechanisms exist.

Continuous low-dose bortezomib treatment yielded only a small number of resistance genes despite analyzing 5 different cell lines, which is consistent with previous findings.[22,53] By using an alternative treatment approach with short-term high-dose bortezomib equivalent to the peak levels in patients,[37] we found in addition inactivation of 2 cell-cycle regulators, *CDK2NC* and *RB1*, to cause resistance. Homozygous deletions of chromosome 1p32.3, including *CDK2NC* and loss of del13q/*RB1*, are recurrent genetic events enriched in relapsed MM and associated with poor outcome.[3,15,54,55] In our cohort, 3 patients had heterozygous loss of *RB1* by chromosome 13q deletion at relapse. The exact mechanism by which loss of function of *CDK2NC* and *RB1* contributes selectively to resistance to bortezomib, but none of the other drugs in MM, remains to be determined. These findings further highlight the need to functionally test different treatment schedules to identify the full spectrum of resistance-causing gene alterations.

Almost all MM patients initially respond to glucocorticoids that are included in most treatment combinations, yet the understanding of the exact mechanism in MM is incomplete. Glucocorticoids induce apoptosis in MM and inhibit NF-κB signaling.[56] Consistently, in our dexamethasone screen, we found several genes, like *TRAF3* and *BIRC3*, whose inactivation enhance NF-κB signaling.[40,57] Furthermore, protocadherin members *PCDHGB4* and *PCDHA5* caused resistance in MM1S cells. *PCDH10*, another member of the protocadherin family, was shown to be a negative regulator of NF-κB and WNT signaling, providing a possible functional connection.[58,59]

Mutations in the large protocadherin gene family, including *PCDHGB4* and *PCDHA5*, are found in ~50% of patients with MM.[4] Despite this high frequency, an association of mutations in protocadherin members with outcome in MM hast not been reported yet. Reasons for this may be that not all protocadherin members affect glucocorticoid response and dexamethasone is virtually always combined with other drugs whose activity was not altered by protocadherin-targeting sgRNAs.

In aggregate, our systematic functional evaluation of relapse-associated mutations found in a cohort of MM patients revealed drivers of resistance and new vulnerabilities for distinct drugs that highly correlate with drug activity in patients (Figure 2). By our integrated approach, we were able to trace gene mutations that functionally alter drug sensitivity. While some of these mutations are known high-risk markers frequently mutated in MM, others, including rare mutations, have not been associated with therapy resistance. Remarkably, we did not observe relevant cross-resistance among the 4 drugs investigated (Figure 2), allowing for tailoring the most active drug combinations according to the genetic profile of a patient. For a slow-growing malignancy such as MM, it may even be feasible to perform a targeted functional genetic screen based on the individual genetic alterations of a patient to guide treatment. Our integrated approach revealed genetic determinants of sensitivity to 4 main MM drugs currently approved for first-line treatment. Surprisingly, sgRNAs targeting *DNAH5*[3,11,13] and *WSCD2* had no impact on any of the drugs despite being among the most recurrently mutated genes acquired at relapse. However, our study was performed in vitro and therefore limited to assess direct drug effects and, due to the unavailability of better models, was performed in cell lines that already harbor many genetic alterations. Future studies need to evaluate the direct and indirect impact of genetic and nongenetic alterations on MM treatments, including antibodies and chimeric antigen receptor T cells as well as combination treatments in more sophisticated model systems like primary patient cells and xenograft models once they become available. Uncovering the genetic determinants of drug sensitivity will help to further facilitate personalized treatment in MM.

Authorship

Contribution: S.R.B., L.K.S., and J.K. designed the study; S.R.B., L.K.S., I.B., T.M., S.K., M.S., and L.R. performed experiments; L.K.S., A.D., T.J.B., M.S., F.D., and L.B. performed, analyzed and interpreted the sequencing analyses; D.M. performed primary sample preparation and fluorescence in situ hybridization analyses; S.R.B., L.K.S., M.K., C.L., H.D., A.L., D.H., F.D., L.B., and J.K. interpreted data; S.R.B., L.K.S., and J.K. took the lead in writing the manuscript; and all authors read and agreed to the final version of the manuscript.

Conflict-of-interest disclosure: J.K. is a member of the advisory committees at Celgene, Takeda, and Janssen. L.B. is a member of the advisory committees at AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, and Seattle Genetics. H.D. is a member of the consulting committees at AbbVie, Agios, Amgen, Astellas, Astex Pharmaceuticals, Celgene, Helsinn, Janssen, Jazz Pharmaceuticals, Novartis, Oxford Biomedicals, and Roche and receives research funding from Amgen, AROG Pharmaceuticals, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Novartis, Pfizer. and Suneisi. A.L. is on the advisory committees at Dialectic Therapeutics; is an equity holder and cofounder of Flash Therapeutics and Vivid Bioscience; and receives research funding from AbbVie, Novartis, and AstraZeneca. F.D. received honoraria from Roche and research funding from Novartis and reports travel accommodations from AbbVie and AstraZeneca. The remaining authors declare no competing financial interests.

ORCID profiles: L.K.S., 0000-0002-6080-6175; T.J.B., 0000-0002-9859-1261; L.R., 0000-0003-1474-8039; J.K., 0000-0002-4649-0506.

Correspondence: Jan Krönke, Department of Hematology, Oncology and Tumor Immunology, Charité−Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany; e-mail: jan.kroenke@charite.de.

References

1. Alexandrov LB, Nik-Zainal S, Wedge DC, et al; ICGC PedBrain. Signatures of mutational processes in human cancer [published correction appears in *Nature*. 2013;502(7470):258]. *Nature*. 2013;500(7463):415-421.

2. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. *Nature*. 2011;471(7339):467-472.

3. Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma [published correction appears in *Blood*. 2018;132(13):1461]. *Blood*. 2018;132(6):587-597.

4. Lohr JG, Stojanov P, Carter SL, et al; Multiple Myeloma Research Consortium. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. *Cancer Cell*. 2014;25(1):91-101.

5. Corre J, Cleynen A, Robiou du Pont S, et al. Multiple myeloma clonal evolution in homogeneously treated patients. *Leukemia*. 2018;32(12):2636-2647.

6. Merz M, Hielscher T, Schult D, et al. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. *Leukemia*. 2020;34(4):1192-1196.

7. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nat Commun*. 2014;5(1):2997.

8. Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. *Blood*. 2016;128(13):1735-1744.

9.   Anderson KC. Progress and Paradigms in Multiple Myeloma. *Clin Cancer Res*. 2016;22(22):5419-5427.

10. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. *N Engl J Med*. 2012;366(19): 1770-1781.

11. Kortüm KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. *Blood*. 2016;128(9):1226-1233.

12. Laganà A, Perumal D, Melnekoff D, et al. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. *Leukemia*. 2018;32(1):120-130.

13. Jones JR, Weinhold N, Ashby C, et al; NCRI Haemato-Oncology CSG. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. *Haematologica*. 2019;104(7): 1440-1450.

14. Van Wier S, Braggio E, Baker A, et al. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. *Haematologica*. 2013;98(10):1586-1592.

15. Chavan SS, He J, Tytarenko R, et al. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. *Blood Cancer J*. 2017;7(2):e535.

16. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol*. 2010; 2(1):a001008.

17. Munawar U, Roth M, Barrio S, et al. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model. *Sci Rep*. 2019;9(1):18062.

18. Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. *Nat Rev Cancer*. 2018;18(2):89-102.

19. Gooding S, Ansari-Pour N, Towfic F, et al. Multiple Cereblon genetic changes associate with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. *Blood*. 2021;137(2):232-237.

20. Liu J, Song T, Zhou W, et al. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. *Leukemia*. 2019;33(1):171-180.

21. Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4^{CRBN} activity. *Blood*. 2018;132(12):1293-1303.

22. Shi CX, Kortüm KM, Zhu YX, et al. CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for bortezomib sensitivity in multiple myeloma. *Mol Cancer Ther*. 2017;16(12):2862-2870.

23. Cocciardi S, Dolnik A, Kapp-Schwoerer S, et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. *Nat Commun*. 2019;10(1): 2031.

24. Arends CM, Galan-Sousa J, Hoyer K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. *Leukemia*. 2018;32(9): 1908-1919.

25. Joung J, Konermann S, Gootenberg JS, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening [published correction appears in *Nat Protoc*. 2019;14(7):2259]. *Nat Protoc*. 2017;12(4):828-863.

26. Szlachta K, Kuscu C, Tufan T, et al. CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. *Nat Commun*. 2018;9(1):4275.

27. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science*. 2014;343(6168): 301-305.

28. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. *Science*. 2014; 343(6168):305-309.

29. Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). *Br J Haematol*. 2014;164(6):811-821.

30. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. *Blood*. 2011;118(18): 4771-4779.

31. Eichner R, Heider M, Fernández-Sáiz V, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. *Nat Med*. 2016;22(7):735-743.

32. Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. *J Clin Oncol*. 2015;33(33):3911-3920.

33. Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature*. 2019;569(7757):503-508.

34. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. *Nucleic Acids Res*. 2019;47(D1):D941-D947.

35. Hurt EM, Thomas SB, Peng B, Farrar WL. Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. *Cancer Biol Ther*. 2006;5(9):1154-1160.

36. Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development [published correction appears in *Cancer Cell*. 2016;30(2):349-351]. *Cancer Cell*. 2010;18(4):367-381.

37. Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Clinical pharmacokinetics and pharmacodynamics of bortezomib. *Clin Pharmacokinet*. 2019;58(2): 157-168.

38. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. *J Clin Oncol*. 2002;20(22):4420-4427.

39. Saita S, Shirane M, Ishitani T, Shimizu N, Nakayama KI. Role of the ANKMY2-FKBP38 axis in regulation of the Sonic hedgehog (Shh) signaling pathway. *J Biol Chem*. 2014;289(37):25639-25654.

40. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell*. 2007; 12(2):131-144.

41. Tessoulin B, Moreau-Aubry A, Descamps G, et al. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. *J Hematol Oncol*. 2018;11(1):137.

42. Mroczek S, Chlebowska J, Kuliński TM, et al. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. *Nat Commun*. 2017;8(1):619.

43. Gaballa S, Saliba RM, Srour S, et al. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. *Am J Hematol*. 2016;91(10):E442-E447.

44. Lakshman A, Painuly U, Rajkumar SV, et al. Impact of acquired del(17p) in multiple myeloma. *Blood Adv*. 2019;3(13):1930-1938.

45. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. *Blood*. 2016;127(24):2955-2962.

46. Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/ GMMG-HD4 trial. *Leukemia*. 2018;32(2):383-390.

47. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. *Blood*. 2005;106(2):698-705.

48. Schweizer MT, Antonarakis ES. Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer. *Clin Adv Hematol Oncol*. 2017;15(10):785-795.

49. Meyer T, Jahn N, Lindner S, et al. Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). *Leukemia*. 2020; 34(2):404-415.

50. Burdak-Rothkamm S, Mansour WY, Rothkamm K. DNA damage repair deficiency in prostate cancer. *Trends Cancer*. 2020;6(11):974-984.

51. Cottini F, Hideshima T, Suzuki R, et al. Synthetic lethal approaches exploiting DNA damage in aggressive myeloma. *Cancer Discov*. 2015;5(9):972-987.

52. Botrugno OA, Bianchessi S, Zambroni D, et al. ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies. *Haematologica*. 2019;105(10):2440-2447.

53. Zhu YX, Tiedemann R, Shi CX, et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. *Blood*. 2011;117(14):3847-3857.

54. Binder M, Rajkumar SV, Ketterling RP, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. *Blood Cancer J*. 2017;7(9):e600.

55. Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. *Leukemia*. 2018;32(1):102-110.

56. Sharma S, Lichtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. *Blood*. 2008;112(4):1338-1345.

57. Lin WW, Yi Z, Stunz LL, Maine CJ, Sherman LA, Bishop GA. The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development. *Sci Signal*. 2015;8(392):ra88.

58. Xu Y, Yang Z, Yuan H, et al. PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/β-catenin/BCL-9 signaling pathway. *Oncol Rep*. 2015;34(2):747-754.

59. Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA. Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. *Mol Cell Biol*. 2008;28(24):7309-7322.